Windlas Biotech shareholding pattern

·Pharma & HealthChart ›

Who owns itSep 2026 quarter

Promoters63.31%no change
Foreign investors (FII)2.08%+0.04 pts
Domestic institutions (DII)7.24%−2.60 pts
of which mutual funds3.10%−2.66 pts
Public27.36%

Per cent of all shares; change on the Jun 2026 quarter, in percentage points. As filed with the exchanges.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

WINDLAS₹888.70

Windlas Biotech Limited

· Pharma & Health
₹ CrorePeersHESTERBIOINDOCOSAIPARENTSYNCOMFPANACEABIONGLFINEHIKALJAGSNPHARMMcap ₹1,876 Cr
Holding % of Total Shares
12 Months Ending
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Q2 FY27
30/09/2026
Promoter & Group62.5162.5162.5162.3462.3461.9961.9961.9063.3163.31
FII / FPI1.592.001.551.521.441.110.930.602.042.08
DII10.359.5810.2610.8911.2111.4311.4411.819.847.24
Mutual Funds8.707.577.116.706.806.396.637.085.763.10
Latest: 2026-09-30 · 24 quarters of history · click a row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.